Mira Pharmaceuticals (MIRA) Net Equity Issued and Repurchased (2022 - 2025)

Mira Pharmaceuticals has reported Net Equity Issued and Repurchased for 3 years, with the latest figure at $3.8 million in Q4 2025.

• Quarterly Net Equity Issued and Repurchased rose 700.85% year-over-year to $3.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.0 million (up 321.11% YoY) and the FY2025 annual result came in at $7.0 million, up 94.18% from the prior year.
• Net Equity Issued and Repurchased grew to $3.8 million in Q4 2025 per MIRA's latest filing, from $2.8 million in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $3.8 million in Q4 2025 and troughed at $3381.0 in Q1 2025.
• A 3-year average of $1.2 million and a median of $478929.0 in 2024 frame the typical range for Net Equity Issued and Repurchased.
• The widest YoY moves for Net Equity Issued and Repurchased: up 700.85% in 2025, down 700.85% in 2025.
• Over 3 years, Net Equity Issued and Repurchased stood at $285000.0 in 2022, then jumped by 68.05% to $478929.0 in 2024, then surged by 700.85% to $3.8 million in 2025.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $3.8 million, $2.8 million, and $345321.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.